A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.
about
Development of Medical Countermeasures to Middle East Respiratory Syndrome CoronavirusAnti-infective immunoadhesins from plants.Receptor-binding domain-based subunit vaccines against MERS-CoVMERS-CoV spike protein: a key target for antivirals.From SARS to MERS: evidence and speculation.A review of treatment modalities for Middle East Respiratory Syndrome.Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike proteinReceptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus.Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like diseaseDevelopment of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infectionsReceptor recognition mechanisms of coronaviruses: a decade of structural studies.Laboratory investigation and phylogenetic analysis of an imported Middle East respiratory syndrome coronavirus case in GreeceReceptor usage and cell entry of porcine epidemic diarrhea coronavirusMulti-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus.Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.Evaluation of candidate vaccine approaches for MERS-CoV.Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27Microevolution of Outbreak-Associated Middle East Respiratory Syndrome Coronavirus, South Korea, 2015Treatment strategies for Middle East respiratory syndrome coronavirus.Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015.Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection.Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines.Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.Vaccines for the prevention against the threat of MERS-CoV.A unified mechanism for aminopeptidase N-based tumor cell motility and tumor-homing therapy.Middle East respiratory syndrome: current status and future prospects for vaccine development.Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV).Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and ProtectSingle-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infectionA recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo.Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset.Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS).Current status on the development of pseudoviruses for enveloped viruses.Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape.Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen.Discovery of novel bat coronaviruses in south China that use the same receptor as MERS coronavirus.
P2860
Q26700054-5AA53925-2332-445B-9CB6-11E708960881Q26799080-C4B6712D-7110-4323-B02B-B64B20644605Q26851979-B3F20E30-8F0C-469A-8349-D36FE77F48FBQ30240139-3F2F004A-7E9A-4BCE-A923-32E4BC97CB36Q30244685-7167B3F2-5F77-4553-B2A7-3B641C6EBC18Q30248209-853820AF-02EB-40B9-BA66-057BB362FC38Q30371303-031E08D6-C366-4D3F-B54C-FD4D78821BCDQ30402347-279C293B-9226-4B1B-A779-6B2344167C4BQ34120263-1EEC92DA-5973-42BC-B158-6EAF89F38FBAQ34324907-E7B7E8CF-E2F5-4B56-B16F-082E6D321148Q34468689-17C046EA-2F57-4661-8DE8-68F387CBB691Q35019893-3BB8FE99-C27E-42BD-A188-F910BE30ED4CQ35115572-54A3B479-18E7-4B94-B347-6B58C85BA392Q35546907-0A31444E-D3E4-4F88-B964-FA389A5CEA5CQ35641223-D05A0D98-0235-440C-BA50-F7F766C8D773Q35877765-224F3777-BDE7-4752-A7E6-6158DE7DD25AQ35887626-9A689C78-BA84-4A13-8584-05C219D762B2Q35917397-504A1129-26F6-4E8F-BAD0-91E91979592CQ35964208-F312E1D0-C165-4EE8-ABD9-B6A800DA1A2BQ36525303-DD8438EE-C88B-48DB-988D-27CA7C9A6AC4Q36555622-662BC05D-44AF-42D5-B0F5-9DAFE555DE78Q37169882-E9391331-A409-4A7F-9632-26053CA52E77Q37188934-81F949EF-ECAC-402A-9AA1-70FF208C24A1Q37434385-77942F57-29D5-45B9-BEB3-4F570AB9D369Q37512915-88C73BE3-A83F-4286-9A9D-8E192B51460EQ37717377-C6660947-6286-4B35-BAED-687EEE7EC44BQ38778044-085D1148-7860-430B-83D7-2B3232F1E982Q38943609-1AF862AE-12E5-43D9-BEEF-BC22EDB7D3D2Q38959242-EB8C8062-5C52-46DA-94E6-BEF9FB3B4FE3Q39034541-CA076AD3-DEC4-4D01-B9F8-FE23FFDC920BQ39574405-DF4D7C5C-401D-45BB-A684-E1604DF22381Q39677274-2DD73A45-0925-4C58-B6C8-D789A2DBCE9AQ40503787-E916BF99-1AC5-4796-AA3E-CC2B78D4A0ADQ40787125-DBB9F72A-E8E0-4F62-8E86-B75C9D6A76F2Q41096904-9D716A6E-2070-4A91-8B1F-0EAAC918070EQ42613915-D3C069C2-398D-442D-9389-97D45E786B48Q47568014-D77E43AE-4514-4BAF-BAF6-65D7542767DAQ51149122-C68DC3CD-B2A0-425B-A695-D1EFF03BBF18Q51730564-F39AE925-1F0B-4DDD-8551-1EBD9F07CBD1Q52579746-4FF83712-B25D-4E19-BAE1-C7857CFEA6ED
P2860
A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A conformation-dependent neutr ...... ome coronavirus spike protein.
@ast
A conformation-dependent neutr ...... ome coronavirus spike protein.
@en
type
label
A conformation-dependent neutr ...... ome coronavirus spike protein.
@ast
A conformation-dependent neutr ...... ome coronavirus spike protein.
@en
altLabel
A conformation-dependent neutr ...... rome coronavirus spike protein
@en
prefLabel
A conformation-dependent neutr ...... ome coronavirus spike protein.
@ast
A conformation-dependent neutr ...... ome coronavirus spike protein.
@en
P2093
P2860
P50
P921
P356
P1433
P1476
A conformation-dependent neutr ...... rome coronavirus spike protein
@en
P2093
Chien-Te K Tseng
Guangyu Zhao
Hongjie Qiu
Shihui Sun
Xinrong Tao
Yusen Zhou
Zhihua Kou
P2860
P304
P356
10.1128/JVI.00433-14
P407
P577
2014-04-09T00:00:00Z